The effective disintegration, dissolution and eventual absorption of
dipyridamole in tablet or suspension form depends upon having a low pH in the stomach. Drugs that significantly raise the gastric pH are expected to reduce the bioavailability of
dipyridamole tablets. This effect has been seen with
lansoprazole.
The
clinical significance of this interaction is unknown. Bear it in mind if a proton pump inhibitor is given with
dipyridamole. Note that modified-release prepar- ations of
dipyridamole (that are buffered) do not appear to be affected.